Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6690080.pdf
Reference26 articles.
1. Bork, E., Ersbøll, J., Dombernowsky, P., Bergman, B., Hansen, M. & Hansen, H. H. (1991). Teniposide and etoposide in previously untreated small-cell lung cancer: a randomised study. J Clin Oncol 9: 1627–1631.
2. Bork, E., Hirsch, F. R., Jeppesen, N., Lassen, U., Vallentin, S., Østerlind, K., Mejer, J., Ingeberg, S., Bergman, B. & Dombernowsky, P. (1997). Oral etoposide (VP-16) every 3 wks. or continuously to elderly patients with small cell lung cancer (SCLC). Preliminary results of a randomaized study. Lung Cancer 18: (suppl.1) 25
3. Fetscher, M., Brugger, W., Engelhardt, R., Kanz, L., Hasse, J., Frommhold, H., Wenger, M., Lange, W. & Mertelsmann, R. (1997). Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. Ann Oncol 8: 49–56.
4. Girling, D. J., Hopwood, P., Lallemand, G., Machin, D., Stephens, R. J. & Baily, A. J. (1996a). Randomised trial of four-drug vs. less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer 73: 406–413.
5. Girling, D., Thatcher, N., Clark, P. I., Hopwood, P., Twiddy, S. & Stephens, R. J. (1996b). Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Group. Lancet 31: 563–566.
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3;Clinical Lung Cancer;2023-11
2. Factors associated with early lung cancer mortality: a systematic review;Expert Review of Anticancer Therapy;2021-06-30
3. The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors;Clinical Lung Cancer;2020-11
4. Therapie des kleinzelligen Lungenkarzinoms bei neu diagnostizierten Patienten mit schlechtem Performance-Status;Kompass Onkologie;2020
5. Cancer of the Lung;Abeloff's Clinical Oncology;2020
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3